Literature DB >> 28911356

High completion rates of isoniazid preventive therapy among persons living with HIV in Swaziland.

L V Adams1, N Mahlalela2, E A Talbot1, M Pasipamire3, S Ginindza2, M Calnan2, S Haumba2.   

Abstract

SETTING: Five human immunodeficiency virus (HIV) care facilities in Swaziland.
OBJECTIVE: To assess adherence and treatment completion of a 6-month course of isoniazid preventive therapy (IPT) provided to HIV-infected patients through a self-selected model of facility-based, community-based or peer-supported IPT delivery coordinated with antiretroviral refills.
DESIGN: Prospective cohort study.
RESULTS: Between February and August 2015, we enrolled 908 patients, with follow-up until February 2016. Most were female (66.2%), with a median age of 38 years (interquartile range 31-45). Most (n = 797, 87.8%) chose facility-based delivery, 111 (12.2%) selected community-based delivery, and none selected peer-supported delivery. Adherence was high in both cohorts; among those with available data, 794 (94.8%) reported taking at least 80% of their IPT (P > 0.05). Twenty-two patients screened positive for tuberculosis (TB) at any visit; all had TB excluded and most continued IPT. In total, 812 (89.4%) patients completed treatment: 711 (89.2%) were on facility-based and 111 (91.0%) on community-based IPT (P > 0.05). No confirmed treatment failures occurred. Few patients discontinued IPT (6.3%) or were lost to follow-up (4.1%).
CONCLUSION: Self-selected IPT delivery aligned with HIV care achieved high rates of adherence and treatment completion. This model may improve outcomes by simplifying clinic visits and conferring agency to the patient, and may be readily implemented in similar high TB-HIV burden settings.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28911356     DOI: 10.5588/ijtld.16.0946

Source DB:  PubMed          Journal:  Int J Tuberc Lung Dis        ISSN: 1027-3719            Impact factor:   2.373


  8 in total

1.  Assessment of Isoniazid Preventive Therapy Outcome Among People Living with HIV in a Referral Hospital, Northeast Ethiopia.

Authors:  Yohannes Mengesha; Muhammed Ahmed
Journal:  Integr Pharm Res Pract       Date:  2020-09-10

2.  TB preventive therapy for people living with HIV: key considerations for scale-up in resource-limited settings.

Authors:  I Pathmanathan; S Ahmedov; E Pevzner; G Anyalechi; S Modi; H Kirking; J S Cavanaugh
Journal:  Int J Tuberc Lung Dis       Date:  2018-06-01       Impact factor: 2.373

3.  Utilization of isoniazid prophylaxis therapy and its associated factors among HIV positive clients taking antiretroviral therapy at Fre Semaetat primary hospital, Hawzien districts, Tigrai, Northern Ethiopia.

Authors:  Haftom Legese; Hagos Degefa; Aderajew Gebrewahd; Haftay Gebremedhin
Journal:  Trop Dis Travel Med Vaccines       Date:  2020-06-17

4.  Outcomes of isoniazid preventive therapy among people living with HIV in Kenya: A retrospective study of routine health care data.

Authors:  Muthoni Karanja; Leonard Kingwara; Philip Owiti; Elvis Kirui; Faith Ngari; Richard Kiplimo; Maurice Maina; Enos Masini; Elizabeth Onyango; Catherine Ngugi
Journal:  PLoS One       Date:  2020-12-02       Impact factor: 3.240

5.  Early-phase scale-up of isoniazid preventive therapy for people living with HIV in two districts in Malawi (2017).

Authors:  Scott A Nabity; Laurence J Gunde; Diya Surie; Ray W Shiraishi; Hannah L Kirking; Alice Maida; Andrew F Auld; Michael Odo; Andreas Jahn; Rose K Nyirenda; John E Oeltmann
Journal:  PLoS One       Date:  2021-04-01       Impact factor: 3.240

6.  Integrated and patient-selected care facilitates completion of isoniazid preventive therapy in Eswatini.

Authors:  L V Adams; T S B Maseko; E A Talbot; S W Grande; M M Mkhontfo; Z Z Simelane; A A Achilla; S M Haumba
Journal:  Public Health Action       Date:  2019-12-21

7.  A systematic review of the number needed to screen for active TB among people living with HIV.

Authors:  L H Chaisson; F Naufal; P Delgado-Barroso; H S Alvarez-Manzo; K O Robsky; C R Miller; J E Golub; A E Shapiro
Journal:  Int J Tuberc Lung Dis       Date:  2021-06-01       Impact factor: 3.427

8.  Successful implementation of isoniazid preventive therapy at a pediatric HIV clinic in Tanzania.

Authors:  Olivia F Hunter; Furaha Kyesi; Amrit Kaur Ahluwalia; Zeinabou Niamé Daffé; Patricia Munseri; C Fordham von Reyn; Lisa V Adams
Journal:  BMC Infect Dis       Date:  2020-10-07       Impact factor: 3.090

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.